曲楠 董金凯 赵立 麦海星 陈彪 陈立军.更昔洛韦在D+/R+肾移植术后预防CMV 感染的疗效观察[J].,2016,16(5):891-893 |
更昔洛韦在D+/R+肾移植术后预防CMV 感染的疗效观察 |
Prophylactic Treatment of Ganciclovir to Prevent Cytomegalovirus Infectionin D+/R+ Renal Allograft Recipients |
|
DOI: |
中文关键词: 肾移植 巨细胞病毒 更昔洛韦 预防性用药 |
英文关键词: Kidney transplantation Cytomegalovirus Valganciclovir Prophylaxis |
基金项目: |
|
摘要点击次数: 1348 |
全文下载次数: 10 |
中文摘要: |
目的:观察D+/R+肾移植术后人群应用更昔洛韦预防巨细胞病毒感染的疗效与安全性。方法:我院2003 年5 月至2011 年
11 月期间D+/R+ 同种异体肾移植患者93 例,肾移植术后预防性应用更昔洛韦,对移植后1 年内巨细胞病毒的感染率、感染发生
的时间及有症状的CMV 发病率进行以及用药后不良事件进行分析。结果:在D+/R+ 肾移植人群中预防性使用更昔洛韦后的感
染率为28 %,有症状的CMV 发病率4.3 %,病毒血症的平均感染时间为231.3 d,严重不良事件发生率为45.1 %。结论:在D+/R+
肾移植术后患者中预防性更昔洛韦能够预防CMV 感染并且延长CMV 初次感染时间,使D+/R+肾移植患者获益。 |
英文摘要: |
Objective:To assess the efficacy and tolerability of ganciclovir to prevent cytomegalovirus (CMV)infection after renal
transplantation.Methods:93 D+/R+ renal allograft recipients were given Prophylactic treatment of ganciclovir, and the incidence of
CMV infection and the time of infection and adverse event in 1year was observed.Results:In D+/R+ renal allograft recipients who were
received ganciclovir prophylaxis, the incidence of CMV infection were 28 %, and the time to first viremia was 231.3 d. The incidence of
serious adverse events was 45.1 %.Conclusion:Ganciclovir prophylaxis significantly reduces CMV infection in D+/R+ renal allograft
recipients. However, it needs further studies in RCT. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |